|
Media Event:
|
The results and implications of the Landmark ONTARGET
® Trial Programme with a specific focus on cardiovascular care in Asia-Pacific.
|
|---|---|
|
Venue:
|
19th Great Wall International Congress of Cardiology
Background information for medical media outside the US only
Disclaimer
The content of the website has been cleared by Boehringer Ingelheim GmbH in compliance with the legal provisions applicable for German companies. Such provisions vary from country to country and can have an impact on the information we can provide to you.
Thus, please contact us directly in case further information is requested which takes into account the framework in your home country.
contact
Disease & Product (English)
Disease & Product (Mandarin)
Support Information (English)
Support Information (Mandarin)
-
Prof. Antonio Miguel Dans
Department of Medicine, University of the Philippines College of Medicine
Professor Dans received his medical degree and fellowship in cardiology from the University of the Philippines. He currently serves as Chief of the Adult and Medical Research Unit and Chairman of the Medical Research Council of the Philippine General Hospital.
-
Prof. Dayi Hu
Chief of the Heart Centre, Peking University's People's Hospital China
Hu Dayi, MD, FACC, FESC, is a renowned expert in the field of cardiology. He is chief of the Heart Centre at Peking University's People's Hospital; director Clinical Research Institute, School of Public Health, Shanghai Fudan University; academician of International EurAsian Academy of Sciences.
-
Prof. Lisheng Liu
Fu Wai Hospital, Chinese Academy of Medical Sciences China
Professor Liu is president of the World Hypertension League and the Chinese Hypertension League. She is also director of Clinical Trials and the Research Centre for the Chinese Hypertension League in Beijing, China.
Slide Sets English
-
Prof. Jeffrey Probstfield
Co-Director Research Education Core and Director KL2 Program, University of Washington, U.S.A.
Jeffrey L. Probstfield, MD graduated from Pacific Lutheran University and the University Of Washington School Of Medicine. In May 1995 he founded the Clinical Trials Service Unit in the Division of Cardiology at the University of Washington.
Slide Sets English
Slide Sets Mandarin
-
Videos
-
B-Roll Interviews
Watch the B-Roll interviews from the 19th Great Wall International Conference of Cardiology in Beijing from 22nd and 23rd October 2008.
-
Prof. Antonio Miguel Dans
Why is the aspect of tolerability especially important in treating Asian patients? (0:34 min)
- Video(FLV)
-
Prof. Antonio Miguel Dans
How could ACE-intolerant patients be protected from cardiovascular events before TRANSCEND? (0:38 min)
- Video(FLV)
-
Prof. Antonio Miguel Dans
What do the results from ONTARGET and TRANSCEND mean for Asian patients? (0:59 min)
- Video(FLV)
-
Prof. Antonio Miguel Dans
What did ONTARGET show with respect to tolerability of ramipril and telmisartan in Asian patients? (1:02 min)
- Video(FLV)
-
Prof. Antonio Miguel Dans
How do you evaluate the safety and tolerability of telmisartan? (0:28 min)
- Video(FLV)
-
Prof. Lisheng Liu
What is the size of the cardiovascular disease problem in Asia and China? (1:08 min)
- Video (English)(FLV)
-
Prof. Lisheng Liu
How is this problem predicted to grow in the future? (0:25 min)
- Video (English)(FLV)
-
Prof. Lisheng Liu
Are doctors in China and Asia currently well prepared for the cardiovascular disease epidemic? ( 0:26 min)
- Video (English)(FLV)
-
Prof. Lisheng Liu
What do the results of the ONTARGET Trial programme mean for doctors in Asia and China? (0:33 min)
- Video (English)(FLV)
-
Prof. Lisheng Liu
Do you expect these results to impact national treatment guidelines in the region and China? (0:25 min)
- Video (English)(FLV)
-
Prof. Lisheng Liu
What is the size of the cardiovascular disease problem in Asia and China? (1:03 min)
- Video (Mandarin)(FLV)
-
Prof. Lisheng Liu
How is this problem predicted to grow in the future? (0:13 min)
- Video (Mandarin)(FLV)
-
Prof. Lisheng Liu
Are doctors in China and Asia currently well prepared for the cardiovascular disease epidemic? (0:25 min)
- Video (Mandarin)(FLV)
-
Prof. Lisheng Liu
What do the results of the ONTARGET Trial programme mean for doctors in Asia and China? (1:34 min)
- Video (Mandarin)(FLV)
-
Prof. Lisheng Liu
Do you expect these results to impact national treatment guidelines in the region and China? (0:26 min)
- Video (Mandarin)(FLV)
-
Prof. Jeffrey Probstfield
What do the results of TRANSCEND mean for physicians treating high risk cardiovascular patients? (0:31 min)
- Video(FLV)
-
Prof. Jeffrey Probstfield
Would you expect to see the same results for other ARBs? (1:08 min)
- Video(FLV)
-
-
Prof. Jeffrey Probstfield
Why did TRANSCEND reach the hope, but not the primary endpoint? (1:32 min)
- Video(FLV)
-
Prof. Jeffrey Probstfield
In the face of these results - would you treat a patient with telmisartan? (0:23 min)
- Video(FLV)
-
-
Images
-
Prof. Antonio Miguel Dans
Department of Medicine, University of the Philippines College of Medicine
-
Prof. Dayi Hu
Chief of the Heart Centre, Peking University's People's Hospital China
-
Prof. Lisheng Liu
Chief of the Heart Centre, Peking University's People's Hospital China
-
Prof. Jeffrey Probstfield
Chief of the Heart Centre, Peking University's People's Hospital China
-
